Literature DB >> 9057169

Comparison of neuropsychological performance between AIDS-free injecting drug users and homosexual men.

M Concha1, O A Selnes, D Vlahov, T Nance-Sproson, M Updike, W Royal, J Palenicek, J C McArthur.   

Abstract

We performed a cross-sectional comparison of the baseline neuropsychologic performance of 107 injecting drug users and 230 homosexual men participating in two longitudinal studies. Cognitive tests measured attention, memory and psychomotor speed. Using multiple regression modelling, the analysis adjusted for age, IQ score, race, six-month history of alcohol, cocaine, opiates and marijuana use, HIV serostatus and CD4+ lymphocyte count. Injecting drug users showed significantly poorer scores in all neuropsychologic tests in the univariate analysis. However, once adjusted for age, IQ score and race, only Rey Complex Figure tests were significantly worse among injecting drug users. These data indicate that age and IQ score rather than risk group account primarily for the differences in the cognitive performance, regardless of serostatus and CD4+ count.

Entities:  

Mesh:

Year:  1997        PMID: 9057169     DOI: 10.1159/000109674

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  10 in total

1.  Acceleration of HIV dementia with methamphetamine and cocaine.

Authors:  A Nath; W F Maragos; M J Avison; F A Schmitt; J R Berger
Journal:  J Neurovirol       Date:  2001-02       Impact factor: 2.643

2.  Substance Abuse, Hepatitis C, and Aging in HIV: Common Cofactors that Contribute to Neurobehavioral Disturbances.

Authors:  Randi Melissa Schuster; Raul Gonzalez
Journal:  Neurobehav HIV Med       Date:  2012-02-16

Review 3.  Neuropsychological consequences of HIV and substance abuse: a literature review and implications for treatment and future research.

Authors:  Lisa R Norman; Michael Basso; Anil Kumar; Robert Malow
Journal:  Curr Drug Abuse Rev       Date:  2009-05

4.  SIV/macaque model of HIV infection in cocaine users: minimal effects of cocaine on behavior, virus replication, and CNS inflammation.

Authors:  Michael Weed; Robert J Adams; Robert D Hienz; Kelly A Meulendyke; Michael E Linde; Janice E Clements; Joseph L Mankowski; M Christine Zink
Journal:  J Neuroimmune Pharmacol       Date:  2011-05-28       Impact factor: 4.147

5.  Morphine exposure during HIV encephalitis in SCID mice.

Authors:  William R Tyor; Hee Young Hwang; Cari Fritz-French
Journal:  Neurochem Res       Date:  2012-09-11       Impact factor: 3.996

6.  Morphine modulation of toll-like receptors in microglial cells potentiates neuropathogenesis in a HIV-1 model of coinfection with pneumococcal pneumoniae.

Authors:  Raini Dutta; Anitha Krishnan; Jingjing Meng; Subash Das; Jing Ma; Santanu Banerjee; Jinghua Wang; Richard Charboneau; Om Prakash; Roderick A Barke; Sabita Roy
Journal:  J Neurosci       Date:  2012-07-18       Impact factor: 6.167

7.  Isolating cognitive and neurologic HIV effects in substance-dependent, confounded cohorts: a pilot study.

Authors:  Desiree A Byrd; Jessica Robinson-Papp; Monica Rivera Mindt; Letty Mintz; Kathryn Elliott; Quenesha Lighty; Susan Morgello
Journal:  J Int Neuropsychol Soc       Date:  2013-02-28       Impact factor: 2.892

Review 8.  An Update of the Review of Neuropsychological Consequences of HIV and Substance Abuse: A Literature Review and Implications for Treatment and Future Research.

Authors:  Lisa R Norman; Michael Basso
Journal:  Curr Drug Abuse Rev       Date:  2015

9.  Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine.

Authors:  J Turchan; C Anderson; K F Hauser; Q Sun; J Zhang; Y Liu; P M Wise; I Kruman; W Maragos; M P Mattson; R Booze; A Nath
Journal:  BMC Neurosci       Date:  2001-03-02       Impact factor: 3.288

Review 10.  Opioid and neuroHIV Comorbidity - Current and Future Perspectives.

Authors:  Sylvia Fitting; MaryPeace McRae; Kurt F Hauser
Journal:  J Neuroimmune Pharmacol       Date:  2020-09-02       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.